# Innate-like T Cell Biology in the Tumor Microenvironment Implications for Cancer Immunotherapy

## TL;DR

Innate-like T cells detect tumors early but are often suppressed in established tumors, suggesting that restoring their function could improve cancer immunotherapy.

## Contribution

The paper reviews how innate-like T cells function in tumors and proposes strategies to restore their antitumor activity.

## Key findings

- Innate-like T cells detect tumor-associated antigens or stress cues early and support antitumor immunity.
- In established tumors, innate-like T cells are suppressed by reduced antigen presentation, inhibitory signals, and metabolic stress.
- Combination therapies targeting innate-like T cells may improve responses in tumors with poor immunotherapy sensitivity.

## Abstract

What are the main findings?
Innate-like T cells, including iNKT, MAIT, and γδ T cells, detect tumor-associated antigenic or stress cues early and support antitumor immunity.In established tumors, innate-like T cells are often restrained by reduced CD1d or MR1 antigen presentation, increased inhibitory receptor signaling, suppressive cytokines, and metabolic stress within the tumor microenvironment.

Innate-like T cells, including iNKT, MAIT, and γδ T cells, detect tumor-associated antigenic or stress cues early and support antitumor immunity.

In established tumors, innate-like T cells are often restrained by reduced CD1d or MR1 antigen presentation, increased inhibitory receptor signaling, suppressive cytokines, and metabolic stress within the tumor microenvironment.

What are the implications of the main findings?
Restoring iNKT, MAIT, and γδ T cell function will likely require matching therapy to the dominant barrier in a given tumor, such as low CD1d or MR1 availability, high checkpoint signaling, suppressive cytokine activity, or metabolic constraint.Combination strategies that activate innate-like T cells while reducing local suppression, including agonist-based activation, adoptive or engineered cell platforms, checkpoint blockade combinations, and metabolic interventions, may improve responses in tumors with poor immunotherapy sensitivity.

Restoring iNKT, MAIT, and γδ T cell function will likely require matching therapy to the dominant barrier in a given tumor, such as low CD1d or MR1 availability, high checkpoint signaling, suppressive cytokine activity, or metabolic constraint.

Combination strategies that activate innate-like T cells while reducing local suppression, including agonist-based activation, adoptive or engineered cell platforms, checkpoint blockade combinations, and metabolic interventions, may improve responses in tumors with poor immunotherapy sensitivity.

Innate-like T cells (ILTCs) link innate immune responses with adaptive immune functions. This group includes invariant natural killer T (iNKT) cells, mucosa-associated invariant T (MAIT) cells, and γδ T cells. ILTCs detect transformed or stressed cells via non-classical antigen presentation pathways. For example, iNKT cells recognize CD1d-presented glycolipids, MAIT cells respond to MR1-presented metabolites from riboflavin pathways, and γδ T cells sense phosphoantigens through butyrophilin-dependent mechanisms and stress ligands. These features support early tumor control and shape downstream immunity by promoting dendritic cell activation, NK cell function, and priming of tumor-reactive CD8+ T cells. In established tumors, ILTC activity is frequently suppressed. Reduced antigen presentation, inhibitory cytokines, hypoxia, and metabolic constraints, including lactate accumulation and kynurenine production, limit effector responses and promote hyporesponsive states. Transcriptional regulators such as TOX, NR4A family members, and BATF are associated with these programs. This review discusses ILTC roles in tumor surveillance, immune escape, and therapeutic strategies to restore their function.